Research To Practice | Oncology Videos

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 2: Emerging Role of HER2-Targeted Therapy in Advanced Biliary Tract Cancers (BTCs) — Tanios Bekaii-Saab, MD CME information and select publications

Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics: Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00) First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira (32:48) Later-Line Therapy for Advanced NSCLC with an EGFR Mutation — Dr Jänne (1:03:51) Management of NSCLC with an EGFR Exon 20 Mutation — Dr Piotrowska (1:33:33) CME information and select publications

Featuring perspectives from Dr Mrinal Gounder, including the following topics: Epidemiology, classification, genetics and diagnosis of sarcomas (0:00) Contemporary medical treatment of sarcomas (5:29) Targeted therapy for the treatment of sarcomas (9:01) Incidence, pathophysiology, classifications and clinical manifestations of liposarcomas (16:27) Current clinical treatment of dedifferentiated liposarcomas (23:14) Targeting the MDM2-p53 pathway for dedifferentiated liposarcomas (28:20) Available data with MDM2 inhibitors for dedifferentiated liposarcomas (36:37) Emerging research and future directions for dedifferentiated liposarcomas; clinical treatment landscape of desmoid tumors (1:01:22) CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics: Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00) Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42) Other Targets for ADC Therapy in mBC — Prof Schmid (44:59) CME information and select publications

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 2: Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhD CME information and select publications

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 1: Expanding Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) Management — Sara M Tolaney, MD, MPH CME information and select publications

Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics: Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00) Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36) Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03) Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43) Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19) CME information and select publications

Featuring an interview with Dr Michiel van der Heijden, including the following topics: Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00) Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adverse events (3:15) Activity of anti-PD1/PD-L1 and anti-CTLA4 combinations for patients with bladder cancer; role of circulating and urinary tumor DNA in urothelial carcinoma (6:40) Case: A 61-year-old woman with metastatic urothelial bladder cancer (mUBC) treated with first-line enfortumab vedotin and pembrolizumab (19:34) Case: A 63-year-old man with extensive mUBC whose disease progresses on avelumab maintenance receives enfortumab vedotin (25:54) CME information and select publications

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications

Featuring an interview with Prof Giuseppe Curigliano, including the following topics: Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00) Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02) Selection and sequencing of treatment for patients with HR-positive, HER2-negative disease who experience progression on CDK4/6 inhibition (9:40) Current and future role of HER2-targeted therapy for HER2-low and HER2-ultralow mBC (19:46) Selection and sequencing of therapy for patients with metastatic triple-negative breast cancer (29:53) Emerging innovative interventions for the treatment of mBC (37:17) CME information and select publications

Featuring an interview with Dr Angeles Alvarez Secord, including the following topics: Front-line management of ovarian cancer (0:00) Management of relapsed/refractory ovarian cancer (20:06) Management of microsatellite instability-high/mismatch repair-deficient endometrial cancer (23:20) Management of microsatellite stable/mismatch repair-proficient endometrial cancer (33:13) Targeted therapy for gynecologic cancers (44:15) CME information and select publications

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Professor Solange Peters, MD, PhD CME information and select publications

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Professor Ben Solomon, MBBS, PhD CME information and select publications

Featuring perspectives from Prof Solange Peters and Prof Ben Solomon, including the following topics: Introduction (0:00) Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Prof Peters (9:17) Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Prof Solomon (33:01) CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Case: A woman in her late 40s who received treatment for triple-negative breast cancer develops lung metastases 2 years later (0:00) Clinical trials investigating TROP2-targeting antibody-drug conjugates (13:28) Identifying and targeting HER2 in HER2 low-expressing disease (21:17) Case: A woman in her early 50s who received treatment for Stage I breast cancer later develops multiple lesions similar to the original cancer (29:00) Thresholds of HER2 expression and the efficacy of trastuzumab deruxtecan (T-DXd) (34:01) Case: A woman in her late 50s receiving T-DXd for HER2-low metastatic breast cancer develops asymptomatic ground glass infiltrates in the lung (39:19) Novel ADC strategies under investigation (48:22) CME information and select publications

Featuring perspectives from Dr Melissa Johnson, Dr Ticiana Leal and Dr Manish Patel, including the following topics: Introduction: Two Faces of Lung Cancer Research (0:00) B7-H3-Targeted Antibody-Drug Conjugates for Lung Cancer — Dr Patel (16:14) Potential Role of Tumor Treating Fields in the Management of Metastatic Non-Small Cell Lung Cancer — Dr Leal (32:36) Emerging Role of Bispecific T-Cell Engaging Immunotherapy in Small Cell Lung Cancer — Dr Johnson (46:14) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates for MM — Jesús G Berdeja, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Thomas Martin, MD CME information and select publications

Featuring perspectives from Dr Jesús G Berdeja and Dr Thomas Martin, including the following topics: Introduction: Real-World Regulatory Issues in Multiple Myeloma (MM) (0:00) Newly Diagnosed MM (14:30) Novel Agents for Relapsed/Refractory MM (24:58) Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies (44:28) CME information and select publications

Featuring perspectives from Dr Evan J Lipson, including the following topics: Introduction: Johns Hopkins University (0:00) Metastatic Melanoma (8:21) Nonmetastatic Melanoma and Other Skin Cancers (34:20) CME information and select publications

Featuring an interview with Dr Joyce O'Shaughnessy, including the following topics: Overview of CDK Inhibition for Metastatic Breast Cancer (0:00) Features of High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (7:45) Sequencing and Selection of CDK4/6 Inhibitors (23:28) Management of Toxicities Associated with CDK Inhibitors and Promoting Patient Adherence (45:47) Review of Clinical Investigator Survey Results (1:01:47) CME information and select publications

Featuring perspectives from Dr Matthew Gubens, including the following topics: Introduction: Risk of Autoimmune Toxicity with Checkpoint Inhibitors (0:00) Immunotherapy in the Neoadjuvant/Adjuvant Setting (7:33) Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (15:45) First-Line Immunotherapy for Metastatic NSCLC (24:04) Novel Agents and Strategies (30:39) Immunotherapy for NSCLC with a Targetable Mutation (41:34) Small Cell Lung Cancer (47:06) CME information and select publications

Featuring an interview with Dr Matthew R Smith, including the following topics: Selection and sequencing of androgen-targeting therapies (0:00) Evidence-based selection of treatment for metastatic hormone-sensitive prostate cancer (25:07) New considerations with the use of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (27:44) Role of novel radiopharmaceuticals for mCRPC (37:09) Promising investigational approaches for prostate cancer (42:38) CME information and select publications

Featuring an interview with Dr Kimberly H Allison, including the following topics: Contemporary practices in pathology and reporting biomarkers of interest (0:00) HER2 testing across numerous solid tumor types (2:47) ER-low reporting category and pathologic interpretation (6:28) PD-1/PD-L1 testing methodology and challenges with bone biopsies (10:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Kimberly H Allison, including the following topics: Pathological assessment of HER2 and appropriate testing methodologies (0:00) Effect of the DESTINY-Breast04 study on clinical practice (12:32) Relevancy of HER2-ultralow expression and implications of the DESTINY-Breast06 study (22:53) Future directions in the pathological and clinical assessment of HER2-positive breast cancer (31:06) CME information and select publications

Featuring perspectives from Dr Dana M Chase, including the following topics: Introduction: ASCO 2024 Review (0:00) Ovarian Cancer (14:29) HER2 as a Therapeutic Target (29:18) Endometrial Cancer (38:55) Cervical Cancer (51:11) CME information and select publications

Featuring an interview with Dr Jonathan W Goldman, including the following topics: Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05) Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16) Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29) CME information and select publications

Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics: Introduction (0:00) Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49) Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54) CME information and select publications

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics: Introduction (0:00) Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27) CME information and select publications

Featuring perspectives from Dr Scott Kopetz and Dr John Strickler, including the following topics: Introduction (0:00) Recent Therapeutic Advances in Colorectal Cancer (CRC) — Dr Strickler (1:53) New Developments in Targeted Therapy for Metastatic CRC — Dr Kopetz (35:11) CME information and select publications

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics: Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00) Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13) Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20) Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49) CME information and select publications

Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur, including the following topics: Introduction (0:00) Case: A woman in her mid 80s with a 2.7-cm residual tumor after neoadjuvant pembrolizumab/chemotherapy for localized triple-negative breast cancer (TNBC) — Ranju Gupta, MD (3:31) Question and Comments: Approach to neoadjuvant therapy and defining residual disease; PD-L1 status and efficacy of pembrolizumab in the localized and metastatic settings — Kapisthalam (KS) Kumar, MD (8:04) Case: A woman in her mid 60s with node-positive TNBC and a single lung metastasis who receives neoadjuvant therapy based on the KEYNOTE-522 trial — Dr Kumar (17:18) Case: A woman in her early 70s with localized TNBC and residual disease after poorly tolerated neoadjuvant pembrolizumab/chemotherapy and lumpectomy — Dr Kumar (23:29) Case: A woman in her late 60s with widely metastatic ER-negative, HER2-low disease after multiple lines of treatment — CDH1 and ERBB2-V697L mutations, microsatellite stable, tumor mutational burden 3 mut/Mb — Dr Gupta (29:13) Question and Comments: Adjuvant therapy selection for patients with localized TNBC with a BRCA mutation and residual disease; risk of acute myeloid leukemia/myelodysplastic syndromes associated with PARP inhibitor therapy — Dr Kumar (40:52) Case: A woman in her early 70s who develops recurrent metastatic ER-negative, HER2-low breast cancer after nab paclitaxel/atezolizumab and receives sacituzumab govitecan — Dr Gupta (46:49) CME information and select publications

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O'Donnell, moderated by Dr O'Donnell, including the following topics: Introduction (0:00) Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05) Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06) Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O'Donnell (39:25) CME information and select publications

Featuring perspectives from Dr Rebecca S Heist, Dr Luis Paz-Ares and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations — Dr Paz-Ares (1:28) Emerging Role of TROP2-Targeted ADCs for NSCLC — Dr Sands (23:12) Other Promising Targets for ADCs for Lung Cancer — Dr Heist (39:07) CME information and select publications

Featuring perspectives from Dr Aaron T Gerds, including the following topics: Introduction: Myelofibrosis (MF) for Oncology "Newbies" (0:00) Biology of MF (5:20) Management of Anemia in MF (20:12) Novel Strategies for MF (29:28) Journal Club (46:12) CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Dr Andrew J Armstrong, Dr Tanya B Dorff and Dr Matthew R Smith, moderated by Dr Armstrong, including the following topics: Introduction (0:00) Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Dorff (3:34) Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Smith (26:32) New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (53:27) Role of Novel Radiopharmaceuticals for mCRPC — Dr Armstrong (1:15:36) Promising Investigational Approaches for Patients with Prostate Cancer — Dr Antonarakis (1:36:43) CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Harold J Burstein, Prof Giuseppe Curigliano, Dr Sara A Hurvitz, Dr Hope S Rugo and Dr Joyce O'Shaughnessy, moderated by Dr Rugo, including the following topics: Introduction (0:00) Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Hurvitz (4:38) Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Burstein (30:11) Selection and Sequencing of Treatment for Patients with HR-Positive, HER2-Negative mBC Who Experience Disease Progression on CDK4/6 Inhibition — Dr Rugo (48:15) Current and Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Prof Curigliano (1:07:24) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:22:11) Current and Future Strategies for the Care of Individuals with Endocrine-Refractory HR-Positive mBC — Dr Bardia (1:42:24) CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Mansoor Raza Mirza, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Brian M Slomovitz, with cases presented by Dr Eric H Lee, Dr Priya Rudolph and Dr Lyndsay J Willmott, moderated by Dr Secord, including the following topics: Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Salani Introduction (0:00) Case: A woman in her mid 60s with dementia who has peritoneal carcinomatosis with OC — Eric H Lee, MD, PhD (3:00) Case: A woman in her mid 40s with advanced OC undergoes immediate cytoreduction — Lyndsay J Willmott, MD (9:52) Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr Backes Case: A woman in her late 40s with a BRCA2 germline mutation and high-grade serous OC — Priya Rudolph, MD, PhD (26:44) Case: A woman in her mid 50s with platinum-sensitive recurrent OC who had not received a prior PARP inhibitor — Dr Willmott (33:35) First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Mirza Case: A woman in her early 60s diagnosed with endometrioid cancer presents with abdominal pain 2 years later — Dr Rudolph (49:44) Case: A woman in her early 70s with microsatellite instability-high, mismatch repair-deficient Stage IV carcinosarcoma — Dr Willmott (56:44) Current Therapeutic Options for R/R EC; Novel Investigational Strategies — Dr Slomovitz Case: A woman in her early 60s with a history of serous endometrial cancer (EC) presents with recurrent disease 2 years later — Dr Rudolph (1:12:44) Case: A woman in her late 70s with EC develops a cough 2 years after initial treatment — Dr Lee (1:19:50) Role of HER2-Targeted Therapy in the Management of Advanced OC, EC and Other Gynecologic Cancers — Dr Secord Case: A woman in her late 60s with endometrioid adenocarcinoma is admitted with abdominal distention — Dr Rudolph (1:34:55) Case: A woman in her mid 30s with mucinous adenocarcinoma of the ovary is later diagnosed with a liver metastasis — Dr Lee (1:41:02) CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22) The Incidence and Management of Interstitial Lung Disease with ADCs (34:05) ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02) ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53) NCPD information and select publications

Featuring perspectives from Dr Robin K (Katie) Kelley, Dr Edward Kim and Prof Arndt Vogel, and moderated by Dr Kelley, including the following topics: Introduction (0:00) Recent Developments in the Management of Early- and Intermediate-Stage Hepatocellular Carcinoma (HCC) — Dr Kim (1:58) First-Line Therapy for Advanced HCC and Biliary Tract Cancers (BTCs) — Prof Vogel (22:24) Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Kelley (42:19) CME information and select publications

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics: Introduction (0:00) Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37) Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23) Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15) Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44) CME information and select publications

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics: Introduction (0:00) The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21) The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18) Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27) Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40) NCPD information and select publications

Featuring perspectives from Dr Petros Grivas, including the following topics: Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00) Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16) Perspective on recurrence mechanisms of NMIBC (22:21) Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27) Importance of collaborative care for patients with bladder cancer (42:02) Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57) Monitoring and management of T-DXd-associated side effects (1:00:47) Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32) Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22) Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer's disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12) CME information and select publications

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, including the following topics: Introduction (0:00) Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49) Case: A woman in her mid 20s with HR-positive, HER2-positive intraductal carcinoma (IDC) who received ovarian suppression with TAC chemotherapy and concurrent trastuzumab/pertuzumab followed by tamoxifen (30:48) Case: A woman in her late 30s with HR-positive, HER2-negative IDC and no nodal involvement who received postoperative chemoradiation therapy followed by tamoxifen and is considering ovarian suppression (39:31) Role of OFS in Preserving Fertility and/or Ovarian Function in Premenopausal Patients – Dr Mayer (44:55) Case: A woman in her early 30s with HR-positive, HER2-positive (IHC 3+) IDC recommended to receive perioperative TCHP who is interested in fertility preservation (1:11:15) Case: A woman in her mid 30s presenting with ER-positive, HER2-negative breast cancer during early pregnancy who received preoperative TAC and had pathologic complete response at surgery (1:14:18) Tolerability and Toxicity of OFS – Dr Kaklamani (1:21:21) Case: A woman in her mid 30s, uninterested in fertility preservation, who received chemotherapy and TAC followed by tamoxifen and abemaciclib for ER-positive, HER2-negative breast cancer (1:39:42) Case: A premenopausal woman in her late 40s with a 3.6-cm breast tumor and a Recurrence Score (RS) of 26 who becomes amenorrheic with chemotherapy and TC (1:43:32) Other Practical Considerations in the Application of OFS – Dr Wander (1:46:29) Case: A woman in her early 50s with HR-positive, HER2 IHC 2+ invasive lobular carcinoma and a RS of 15 who declined chemotherapy and opted to stop adjuvant leuprolide after 1 year (1:59:56) Case: A woman in her early 40s with HR-positive, HER2 IHC 1+ breast cancer who has no interest in fertility preservation and significant residual disease at surgery (2:14:06) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches for Patients with NSCLC and Other Actionable Genomic Alterations — Justin F Gainor, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Karen Reckamp, MD, MS CME information and select publications

Featuring perspectives from Dr Justin F Gainor and Dr Karen Reckamp, including the following topics: Introduction: Bringing Research into Practice (0:00) EGFR Activating Mutations (14:01) Exon 20 Insertion Mutations (38:06) MET Exon 14 Alterations (41:49) HER2 Mutations and Overexpression (50:27) CME information and select publications

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics: Introduction (0:00) The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30) The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53) First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16) The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16) Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42) Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24) The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32) Tolerability and Other Practical Considerations with ICIs (1:25:57) The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14) The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36) NCPD information and select publications

Featuring perspectives from Dr Matthew D Galsky and Dr Ashish M Kamat, including the following topics: Introduction: Urologist for Life (0:00) Non-Muscle-Invasive Urothelial Bladder Cancer (UBC) Update (9:54) Enfortumab Vedotin/Pembrolizumab Now and in the Future (30:21) HER2-Positive UBC (37:33) Future Directions — ctDNA (55:39) CME information and select publications